Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Regulatory

MSD secures EC approval for Enflonsia to prevent infant RSV infection

 April 20, 2026

Pharmaceutical Business Review

This approval authorises Enflonsia’s marketing across all 27 European Union member states, Iceland, Liechtenstein and Norway.

RegulatoryInfectious DiseaseRead full story

Post navigation

UCB to purchase Neurona and NRTX-1001 for $1.15bn →
← UCB to purchase Neurona and NRTX-1001 for $1.15bn

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com